Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Abstract Background Diabetes mellitus type 2 (DM2) is a risk factor for developing heart failure but there is no specific therapy for diabetic heart disease. Sodium glucose transporter 2 inhibitors (SGLT2I) are recently developed diabetic drugs that primarily work on the kidney. Clinical data descri...

Full description

Bibliographic Details
Main Authors: M. Arow, M. Waldman, D. Yadin, V. Nudelman, A. Shainberg, N. G. Abraham, D. Freimark, R. Kornowski, D. Aravot, E. Hochhauser, M. Arad
Format: Article
Language:English
Published: BMC 2020-01-01
Series:Cardiovascular Diabetology
Subjects:
Diabetes mellitus type 2
Cardiomyopathy
Dapagliflozin
Cardiomyocytes
Calcium transport fibrosis
Inflammation
Online Access:https://doi.org/10.1186/s12933-019-0980-4

Internet

https://doi.org/10.1186/s12933-019-0980-4

Similar Items